Long-term survival after cardiac retransplantation: A twenty-year single-center experience  by John, Ranjit et al.
and acute rejection account for the remainder of cases of
myocardial dysfunction after cardiac transplantation.
Therapeutic interventions for graft failure have included
aggressive immunosuppressive therapy, percutaneous
transluminal coronary angioplasty, coronary artery
bypass grafting, and transmyocardial laser revasculariza-
tion; however, these interventions provide only tempo-
C ardiac transplantation is the only therapeutic modal-ity to achieve long-term survival in the treatment of
end-stage heart disease.1 Despite a growing insight into
the pathogenesis of accelerated coronary artery disease
in cardiac allograft recipients, the latter remains the
major cause of late graft failure and death in patients
undergoing cardiac transplantation.2 Primary graft failure
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rary benefit. The only therapeutic option that has been
shown to obtain a satisfactory long-term outcome for a
failing cardiac allograft is cardiac retransplantation.3
Earlier studies have demonstrated poorer graft and
patient survival after retransplantation than after primary
transplantation.4-6 This poorer outcome coupled with
the increasing donor shortage raises practical and ethi-
cal concerns regarding retransplantation. Accordingly,
we performed a retrospective analysis of patients
undergoing cardiac retransplantation at the Columbia
Presbyterian Medical Center to analyze risk factors that
predict the outcome after retransplantation and evaluate
the survival benefit of cardiac retransplantation.
Patients and methods
Patient selection. Between February 1977 and October
1997, 952 patients underwent cardiac transplantation at the
Columbia Presbyterian Medical Center for the treatment of
end-stage heart disease. Forty-three patients underwent car-
diac retransplantation for cardiac allograft failure resulting
from transplant-related coronary artery disease (n = 33), acute
rejection (n = 7), primary graft failure (n = 2), and cardiac
failure of unknown origin (n = 1). From 1993, our criteria for
the selection of patients for cardiac retransplantation was
revised on the basis of our earlier experience. Patients with
allograft dysfunction resulting from primary graft failure and
those with intractable acute rejection occurring less than 6
months after transplantation were not considered for retrans-
plantation. Our current exclusion criteria for cardiac retrans-
plantation are listed in Table I. Consequently, all patients
undergoing retransplantation after 1993 (n = 19) had cardiac
allograft failure as a result of transplant-related coronary
artery disease, except 1 patient who underwent retransplanta-
tion for intractable acute rejection 10 years after the first
transplant operation.
Operative techniques. Donor hearts were harvested from
beating-heart brain-dead individuals. Grafts were procured
either locally or distantly and they were preserved by cold
cardioplegic arrest with University of Wisconsin solution and
topical hypothermia. Orthotopic cardiac transplantation was
generally performed by means of the technique described by
Lower and Shumway,7 although for the past 5 years a bicav-
al anastomosis has usually been done.
Immunosuppressive regimen. Since 1983 all patients
undergoing transplantation at the Columbia Presbyterian
Medical Center have received cyclosporine-based immuno-
suppression [INN: ciclosporin]. Changes in the immunosup-
pressive protocol have included the following: (1) progres-
sive reduction in the administered dose of cyclosporine, (2) a
change from double-therapy immunosuppression (cyclo-
sporine and corticosteroids) to triple-therapy immunosup-
pression (cyclosporine, azathioprine, and corticosteroids)
since 1985, (3) substitution of intravenous murine monoclon-
al antibody OKT3 (5 mg/day) for cyclosporine for the first 4
days after transplantation for patients who have severe renal
dysfunction, and (4) use of mycophenolate mofetil instead of
azathioprine since 1996.
Current dosing for standard triple-therapy immunosuppres-
sion consists of the following: (1) A preoperative dose of
cyclosporine of 3 to 6 mg/kg is followed by intravenous
cyclosporine (1-2 mg/kg in 24 hours) until oral intake is tol-
erated. Daily oral doses (3-6 mg/kg) are adjusted so that
serum levels are maintained at 300 to 350 mg/dL. (2)
Azathioprine is administered in a preoperative oral dose (4
mg/kg) followed by daily doses of 2 mg/kg intravenously
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Table I. Cardiac retransplantation exclusion criteria*
1. Acute graft failure (since 1993)
2. Intractable acute rejection occurring less than 6 months after 
transplantation (since 1993)
3. Posttransplantation lymphoproliferative disorder
4. Pulmonary hypertension (pulmonary vascular resistance > 3 
Wood units/m2 after vasodilator therapy)
5. Chronic end-organ dysfunction
Serum creatinine > 2 mg/dL
Abnormal hepatic function test results
Chronic obstructive lung disease
Bleeding disorders
6. Evidence of patient noncompliance
7. Asymptomatic peripheral vascular or carotid artery disease
*In addition to standard cardiac transplantation exclusion criteria.
Table II. Variables for analysis of factors affecting
patient survival after retransplantation
1. Demographic variables
Recipient (at retransplantation)
Race
Age
Weight
Height
Age
Cytomegalovirus status
Donor (at retransplantation)
Race
Age
Weight
Height
Age
Cytomegalovirus status
2. Indications for operation
Primary transplantation
Retransplantation
3. Immunologic factors
HLA matching between recipient and second donor
Anti-HLA IgG and IgM antibodies
4. Perioperative factors
Preoperative need for mechanical circulatory support
Hemodynamic stability
Cardiopulmonary bypass time
Ischemic time for donor heart
Ig, Immunoglobulin.
until the patient can tolerate oral medications when azathio-
prine is changed to mycophenolate mofetil starting at a dose
of 1000 mg twice daily. (3) Intravenous methylprednisolone
(500 mg) is administered during the operation and followed
in the postoperative period by 125 mg every 8 hours for 3
doses. Prednisone is then instituted at a daily oral dose of 1
mg/kg and gradually tapered over 4 months to 0.1 mg/kg per
day.
Management of rejection. Rejection was diagnosed by
endomyocardial biopsy and graded according to the
International Society for Heart and Lung Transplantation
(ISHLT) classification of acute rejection.8 Routine treatment
of rejection consisted of an increase in oral prednisone to 100
mg/day for 3 days followed by a taper for 1 week to the base-
line dose. If rejection persisted after a course of oral pred-
nisone therapy, as seen on endomyocardial biopsy, or if rejec-
tion was accompanied by altered hemodynamics, intravenous
methylprednisolone (1 gm daily for 3 days) was used to
reverse rejection. Intravenous OKT3 (5 mg/day) and antithy-
mocyte globulin were used in hemodynamically unstable
patients and in patients with rejection episodes refractory to
intravenous steroid boost. Other modalities attempted for
repeated and persistent rejection have included methotrexate,
total lymphoid irradiation, plasmapheresis, and photophere-
sis. Persistent rejection episodes less than 6 months after
transplantation associated with hemodynamic instability,
The Journal of Thoracic and
Cardiovascular Surgery
Volume 117, Number 3
John et al   545
Fig 1. Actuarial survival of patients undergoing primary cardiac transplantation (PCT) versus patients undergo-
ing retransplantation from the time of the second transplant (RETX). The squares and triangles represent actual
events positioned along the horizontal axis at the time of the event and by the Kaplan-Meier method along the
vertical axis. CI, Confidence interval.
despite all attempted measures, were considered as an indica-
tion for retransplantation before 1993.
Angiography/diagnosis of coronary disease. All patients
underwent annual coronary angiography. The diagnosis of
transplant-related coronary artery disease was based on the
following: (1) discrete lesions resulting in more than 50%
obstruction of the proximal or midportions of major graft ves-
sels or (2) diffuse, concentric narrowing of the whole vessels,
including their branches. If transplant-related coronary artery
disease was identified, the frequency of angiography was
increased to a biannual regimen. Patients are not given rou-
tine vasodilators before coronary injections. All angiograms
are reviewed by a cardiologist and compared with the previ-
ous year’s films to detect the presence of luminal irregulari-
ties, discrete stenoses, and loss of third-order branches or
pruning of vessels. Explanted hearts and autopsy specimens
were examined for evidence of vessel occlusion and irregu-
larities, ischemic damage, and presence of acute cardiac
rejection.
Immunologic studies
Human leukocyte antigen (HLA) typing. Serologic typing
of HLA-A and HLA-B loci was performed by standard
microcytotoxicity techniques. HLA-DR typing was per-
formed by both serologic analysis and DNA techniques with
sequence-specific oligonucleotide primers and the poly-
merase chain reaction.
Detection of anti-HLA antibodies. Sera were obtained from
all patients on the day of transplantation and screened for the
presence of lymphocytotoxic antibodies against separated T
lymphocytes and B lymphocytes obtained from a panel of 70
individuals representative of all HLA class I and class II anti-
gens found in the North American population. Sera were
screened for complement-mediated lytic activity in the pres-
ence or absence of dithioerythritol (DTT). Total T cell panel
reactive antibody was considered positive if serum, in the
absence of DTT, reacted against greater than 10% of the T
cell reference panel.
A prospective panel reactive antibody screen was per-
formed on all patients who underwent transplantation. A neg-
ative prospective donor-specific lymphocyte crossmatch was
required before transplantation when the panel reactive anti-
body titer was in excess of 20%.
Statistical analysis. Data were examined univariately by
the Student t test for continuous variables and Fisher’s exact
test for discrete data (Table II). Actuarial survival of patients
was estimated by Kaplan-Meier analysis, with P values cal-
culated by log-rank statistics.9 For the multivariable survival
analysis after retransplantation, variables with a univariate P
value < .25 were entered into a Cox proportional hazards
model.10 Any possible era effects (influence of year of trans-
plantation) were corrected by stratification in the Cox model.
This model is a multiple regression analysis for examining
time-dependent outcomes and their potential associated risk
factors by modeling a linearized function of a set of P covari-
ates in the log hazard domain. The interpretation of a risk fac-
tor allowed into the model with a P value < .05 is that it is an
independent risk factor associated with the event, over and
above other potential risk factors included in the equation.
The hazard ratio is the ratio of the estimated hazard for those
with the characteristic variable in question to the estimated
hazard for those without, controlling for other variables (or
covariates).10
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Table III. Causes of death in patients undergoing cardiac retransplantation
Indication Interval between Time to death 
No. Diagnosis for ReTx transplants (mo) Cause of death after retransplant (mo)
1 CAD TRCAD 104 Lung cancer 26.7
2 ICM Rejection 0.03 Circulatory collapse 0
3 CAD TRCAD 38 Sepsis 2.6
4 ICM Rejection 0.5 Sepsis 11
5 CAD TRCAD 55.1 Sepsis? Cardiac failure 8.3
6 ICM TRCAD 38.7 Cardiac failure 53.7
7 CAD Rejection 13.3 Pneumonia, sepsis 43.7
8 ICM TRCAD 19.9 Colonic perforation (CMV), sepsis 4.2
9 CAD TRCAD 64.7 Rejection, sepsis 5
10 ICM TRCAD 25.2 Circulatory collapse, ?rejection 0.6
11 CAD TRCAD 59.5 Pancreatitis 7.2
12 ICM Rejection 1.1 Pneumonia, ?sepsis 83.4
13 ICM TRCAD 68.2 Rejection, pneumonia 7
14 CAD TRCAD 14.7 Sepsis 1.9
15 ICM AGF 0.1 Circulatory collapse 0.1
16 CAD TRCAD 0.03 Circulatory collapse 0.1
17 ICM TRCAD 19.2 Arrhythmia 6.6
18 ICM Rejection 9 Pancreatitis, sepsis 1.2
19 ICM AGF 0.03 Circulatory collapse 0
ReTx, Retransplantation; CAD, coronary artery disease; ICM, idiopathic cardiomyopathy; TRCAD, transplant-related coronary artery disease; AGF, acute graft
failure; CMV, cytomegalovirus.
For all statistical analysis, data were analyzed by means of
the SAS System software (SAS Institute, Inc, Cary, NC).
Results
Demographic data. The cause of cardiac failure in
this population of 909 patients consisted of idiopathic
cardiomyopathy (n = 503), ischemic cardiomyopathy (n
= 249), congenital heart disease (n = 66), tumor (n = 6),
and others (n = 83). The mean age at transplantation
was 43.4 ± 18.2 years (range 0.01-70.2 years). The pop-
ulation comprised 702 male and 207 female patients
(male/female ratio 3.4:1). The mean follow-up period
was 3.94 ± 3.5 years (range 0-15.1 years) with a cumu-
lative patient follow-up time of 2762 patient-years.
In the study group, the mean age of patients at pri-
mary transplantation was 37.2 years (range 2-58 years,
SD ± 16.7) and mean age at retransplantation was 41.6
years (range 5-64 years, SD ± 16.6). The original diag-
nosis of end-stage cardiac disease in these 43 patients
was idiopathic cardiomyopathy (29, 66.7%), ischemic
cardiomyopathy (11, 26.2%), and congenital heart dis-
ease (3, 7.1%). The indications for retransplantation
included transplant-related coronary artery disease in
33 patients, rejection in 7 patients, acute graft failure in
2, and cardiac failure of unknown etiology in 1 patient.
This group includes 1 patient who received a third graft
27.6 months after transplant-related coronary artery
disease developed in the second graft (the first graft
failed as a result of acute rejection). The mean follow-
up period after retransplantation was 2.4 ± 2.7 years
(range 0-9.5 years) with a cumulative patient follow-up
time of 103.2 patient-years.
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Fig 2. Actuarial survival of patients undergoing primary cardiac transplantation (PCT) before 1993 versus
patients undergoing cardiac retransplantation (from the time of the second transplant, RETX) before 1993. The
squares and triangles represent actual events, positioned along the horizontal axis at the time of the event and by
the Kaplan-Meier method along the vertical axis. CI, Confidence interval.
The time interval between the 2 transplants for all
patients undergoing retransplantation ranged from 10
hours to 11.4 years (mean 4.4 years, SD ± 3.1 years).
The mean intervals between transplants for patients
undergoing retransplantation for acute graft failure,
rejection, and transplant-related coronary artery disease
were 0.06 months (SD ± 0.04 months), 33.1 months
(SD ± 49.6 months), and 66.3 months (SD ± 31.8
months), respectively. 
Actuarial survival. During the 20-year period, the
actuarial survival of the 909 patients who received a
primary transplant was 76%, 71%, and 60% at 1, 2, and
5 years, respectively. In the 43 patients undergoing
retransplantation, the actuarial survival from the time
of the second transplant was 66%, 66%, and 51% at 1,
2, and 5 years, respectively (Fig 1). The difference in
the actuarial survival between these 2 groups was not
statistically significant (P = .2).
Actuarial survival of patients undergoing trans-
plantation before 1993 versus after 1993. The actu-
arial survival of patients undergoing retransplantation
before 1993 (n = 24) was 46%, 45%, and 33% at 1, 2,
and 5 years, respectively, as compared with 94%, 94%,
and 94% at 1, 2, and 4 years, respectively, for patients
548 John et al The Journal of Thoracic and
Cardiovascular Surgery
March 1999
Fig 3. Actuarial survival of patients undergoing primary cardiac transplantation (PCT) since 1993 versus patients
undergoing cardiac retransplantation (from the time of the second transplant, RETX) since 1993. The squares and
triangles represent actual events, positioned along the horizontal axis at the time of the event and by the Kaplan-
Meier method along the vertical axis. CI, Confidence interval.
undergoing retransplantation after 1993 (n = 19, P =
.003). There was no difference in the follow-up period
after retransplantation for these 2 groups (2.9 ± 0.67
years for the <1993 group vs 1.7 ± 0.29 years for the
>1993 group, P = .13). The interval between trans-
plants for those undergoing retransplantation after
1993 was significantly longer than that of patients
undergoing retransplantation before 1993 (76.4 ± 32.04
months vs 33.6 ± 28.9 months; P < .0001).
The actuarial survival of primary cardiac allograft
recipients undergoing transplantation before 1993 at 1
and 5 years was 72% and 58%, respectively, as com-
pared with actuarial survival of 46% and 33% at 1 and
5 years, respectively, for patients undergoing cardiac
retransplantation before 1993 (P = .004, Fig 2). The
actuarial survival at 1 and 4 years of patients undergo-
ing primary cardiac transplantation since 1993 was
81% and 77%, respectively, as compared with 94% and
94%, respectively, for patients undergoing retransplan-
tation since 1993 (P = .09, Fig 3).
Comparison with 1997 ISHLT registry.11 The four-
teenth official report of the ISHLT registry in 1997
reported survival after retransplantation based on a
retransplant interval of 9 months. According to their
statistics, survival of patients undergoing retransplanta-
tion at an interval of more than 9 months was signifi-
cantly better than that of patients undergoing retrans-
plantation at an interval less than 9 months (P = .001).
However, we did not find a statistical difference
between these 2 groups, although there was a trend
toward improved survival in patients undergoing
retransplantation at an interval of more than 9 months
(P = .08). In comparison with our actuarial survivals of
66%, 66%, and 51% at 1, 2, and 5 years, respectively,
the survivals of all patients undergoing retransplanta-
tion in the 1997 ISHLT registry were 55%, 49.9%, and
43.1% at 1, 2, and 4 years, respectively.
Mortality. Nineteen patients undergoing cardiac
retransplantation died during the period of the study.
The 2 patients undergoing retransplantation for acute
graft failure died as a result of severe cardiovascular
hemodynamic instability, 11 patients died of sepsis of
varying origins, 1 patient died of lung cancer, and the
rest died of cardiovascular instability as a result of
severe rejection, transplant coronary artery disease, and
arrhythmia. The causes of death of these patients, as
well as the indications for primary and retransplanta-
tion, interval between transplants, and the time to
death, are shown in Table III.
Univariate and multivariable analysis. Univariate
analysis revealed a shorter interval between transplants
(P = .003), older age at transplantation (P = .02), non-
white race (P = .02), an initial diagnosis of ischemic
cardiomyopathy (P = .02), and the need for preopera-
tive mechanical circulatory support (P = .02) as statis-
tically significant risk factors for death after retrans-
plantation. Other variables were not statistically
significant (Table IV). However, multivariable analysis
identified only a shorter interval between transplants (P
= .04) and an initial diagnosis of ischemic cardiomy-
opathy (P = .03) as risk factors for death after retrans-
plantation (Table V). Actuarial survival analysis of
patients undergoing cardiac retransplantation at an
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Table IV. Univariate analysis of factors affecting
patient survival after cardiac retransplantation
Risk factor P value
Demographic variables
Age at transplantation .03
Age at retransplantation .09
Male .8
Recipient nonwhite race .02
Recipient height .6
Recipient weight .4
Recipient cytomegalovirus status .4
Donor cytomegalovirus status .8
Time between transplants .003
Year of transplantation .8
Adult versus pediatric patient .04
Indications for operation
Ischemic cardiomyopathy .02
Idiopathic cardiomyopathy .2
Transplant-related coronary artery disease .6
Immunologic variables
HLA-A matching .2
HLA-B matching .5
HLA-DR matching .3
Pretransplantation anti-HLA class I IgG antibody .4
Pretransplantation anti-HLA class II IgG antibody .7
Pretransplantation anti-HLA IgM antibody .7
Perioperative factors
Donor ischemic time .3
Cardiopulmonary bypass time .2
Hemodynamic stability .9
Mechanical circulatory support .02
IgG, Immunoglobulin G.
Table V. Multivariable analysis of factors affecting
patient survival after cardiac retransplantation
Hazard 
Risk factor Coefficient P value ratio 95% CI
Shorter time –0.0192 .04 1.26* 1.01, 1.57
between transplants
Ischemic 1.0595 .03 2.88 1.07, 7.75
cardiomyopathy
CI, Confidence interval.
*For every decrease in interval between transplants by 1 year, the chance of
survival decreases 1.26 times.
interval of less than 24 months after primary transplan-
tation versus more than 24 months after primary trans-
plantation, as well as with and without an underlying
diagnosis of coronary artery disease (ischemic car-
diomyopathy), is shown in Figs 4 and 5.
Development of transplant-related coronary artery
disease in the first and second grafts. In the 43 patients
undergoing retransplantation, the freedom from trans-
plant-related coronary artery disease after the first trans-
plant at 1, 2, and 5 years was 94%, 72%, and 44%, respec-
tively (median time to transplant-related coronary artery
disease was 4.4 years). In comparison, the freedom from
transplant-related coronary artery disease at 1, 2, and 5
years after retransplantation was 92%, 88%, and 50%,
respectively (median time to transplant-related coronary
artery disease after retransplantation was 4.03 years).
Discussion
Despite the development of new surgical techniques
for the treatment of end-stage heart failure, such as
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Fig 4. Actuarial survival of patients undergoing cardiac retransplantation at an interval less than 24 months after
the first transplant versus patients undergoing cardiac retransplantation at an interval more than 24 months after
the first transplant. The squares and triangles represent actual events, positioned along the horizontal axis at the
time of the event and by the Kaplan-Meier method along the vertical axis. CI, Confidence interval.
partial left ventriculectomy,12 improved mechanical
assist devices,13 and further progress in the under-
standing of the immunologic mechanisms in xeno-
transplantation,14 cardiac transplantation remains the
proven therapeutic modality to achieve long-term sur-
vival in these patients. The survival and the quality of
life in these patients has been steadily improving as a
result of advancement in various fields, but the devel-
opment of transplant-related coronary artery disease
and intractable acute rejection continues to be an
impediment to long-term survival. Further, the occur-
rence of cardiac allograft failure in these patients often
poses a therapeutic dilemma to the transplant team
because of the scarcity of donor organs. So far, since
first reported by Copeland and associates15 in 1977,
cardiac retransplantation has been shown to be the
only way to prolong survival. However, earlier results
with cardiac retransplantation have not always been
encouraging enough to justify its routine use. The
recent ISHLT registry identified retransplantation as
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Fig 5. Actuarial survival of patients with underlying ischemic cardiomyopathy (CAD) undergoing cardiac retrans-
plantation versus patients undergoing cardiac retransplantation without underlying ischemic cardiomyopathy (no
CAD). The squares and triangles represent actual events, positioned along the horizontal axis at the time of the
event and by the Kaplan-Meier method along the vertical axis. CI, Confidence interval.
the single most important risk factor for both 1- and 5-
year mortality after adult heart transplantation.11 We
reviewed patients undergoing cardiac retransplantation
to evaluate survival, as well as to identify risk factors
affecting the outcome after retransplantation in these
patients.
Our early experience at the Columbia Presbyterian
Medical Center showed no difference in outcome
between those undergoing primary transplantation and
retransplantation.16 However, the initial number of
patients undergoing retransplantation was relatively
small in that study, and we have since more than tripled
our experience. Further, we have since changed our
selection criteria for retransplantation based on our ini-
tial results, as well as those of others. This study indi-
cates that cardiac retransplantation is an effective ther-
apy for patients with cardiac allograft failure,
especially that resulting from transplant-related coro-
nary artery disease. Long-term 5-year graft survival can
be expected in more than 50% of all patients undergo-
ing retransplantation, and patient survival has exceeded
50% at 10 years.
An analysis of the risk factors affecting outcome after
cardiac retransplantation showed that the interval
between transplants and an initial diagnosis of ischemic
cardiomyopathy are the main determinants of survival.
Patients undergoing retransplantation after a short
interval have a high mortality, in contrast to patients
undergoing transplantation after longer intervals. These
findings are consistent with the data previously report-
ed for patients undergoing cardiac retransplantation
both by other centers3 and by the ISHLT registry
report.10 A possible explanation for the poor outcome
after retransplantation in patients with a primary diag-
nosis of ischemic cardiomyopathy is that these patients
are more likely than other cardiac allograft recipients to
have other end-organ dysfunction owing to generalized
atherosclerosis.
A likely explanation for the relationship between
shorter interval between transplants and survival after
retransplantation is that the same risk factors for shorter
survival of the first allograft are operating to limit sur-
vival of the second allograft. We have recently shown
that the presence of pre-formed immunoglobulin G anti-
bodies against allogeneic major histocompatibility com-
plex class II molecules in retransplant candidates is a
major risk factor for earlier and more frequent episodes
of high-grade rejection after retransplantation.17 More-
over, we have also shown that a high cumulative fre-
quency of high-grade rejections is directly correlated
with significantly earlier onset of transplant-related
coronary artery disease.18 Since the freedom from
development of transplant-related coronary artery dis-
ease after retransplantation was 50% at 5 years, similar
to that with the primary grafts in these patients, this
entity remains a major concern19 and may be the end
result of persistent donor-specific alloreactivity.
Therefore it is very likely that in those individuals with
active antidonor immune responses while the primary
allograft is in place, graft failure occurs earlier, and, in
the absence of modification of the immunosuppressive
regimen, graft failure of the second allograft is also like-
ly to occur sooner. Modification of donor-specific
immune responses by means of intravenous
immunoglobulin or cyclophosphamide, or both, may
have a significant impact on survival of the second allo-
graft.20,21 As for primary transplant patients, it is impor-
tant that aggressive lowering of cholesterol levels, as
well as avoidance of other risk factors such as cigarette
smoking, be pursued in the posttransplantation period
for the prevention of transplant-related coronary artery
disease.22 This comparison of the relationship between
primary transplant time-related survival and that after
retransplantation is limited by the fact that it is a risk-
unadjusted comparison, except for date.
The Stanford group reported that patients undergoing
retransplantation with a creatine level of 2.0 mg/dL or
more have a significantly higher risk of postoperative
dialysis and death than do patients with a creatinine
level less than 2.0 mg/dL.6 As mentioned in Table I, our
exclusion criteria for retransplantation include a creati-
nine level above 2.0 mg/dL. However, simultaneous
kidney transplantation and heart retransplantation is a
possible approach in cardiac retransplant candidates
with elevated creatinine levels.
The optimal timing of retransplantation in patients
with cardiac allograft failure is not always an easy deci-
sion for the transplant team. In cases of primary graft
failure and allograft failure resulting from severe rejec-
tion with its accompanying hemodynamic instability,
retransplantation often offers the last hope for survival
and is thus used as a salvage procedure. This accounts
for the poorer survival in these subgroups of patients,
both in our experience and in that of others.23
Retransplantation for primary graft failure is still
accompanied by a dismally high mortality (100%) in
our experience. On this basis we have revised our
selection criteria so that patients with transplant-relat-
ed coronary artery disease are almost the only ones
undergoing retransplantation. Since 1993, we have not
performed cardiac retransplantation for cardiac allo-
graft recipients with acute graft failure and resistant
acute rejection, except in 1 pediatric cardiac transplant
recipient who underwent retransplantation for rejection
552 John et al The Journal of Thoracic and
Cardiovascular Surgery
March 1999
resistant to treatment 10 years after the primary trans-
plantation. Retransplantation for transplant-related
coronary artery disease should be performed before the
development of noncardiac organ dysfunction denies
the patient an opportunity for retransplantation.
However, for transplant-related coronary lesions
amenable to interventions other than retransplantation,
such as angioplasty and coronary artery bypass graft-
ing, it is important that the latter be attempted together
with aggressive immunosuppressive therapy before
retransplantation is attempted.24-26
Despite the conclusions derived from this study, the
limitations are primarily related to the relatively small
number of retransplant patients as compared with the
primary transplant patients. Although we and others
have shown that immunologic factors such as the pres-
ence of pretransplant anti-HLA immunoglobulin G
antibodies are associated with adverse outcomes after
transplantation,17,18,27 immunologic variables were not
determinants of patient survival after retransplantation
in this study. Again, a small sample size limits the
strength of the statistical analysis performed. Multi-
center-based studies such as the ISHLT registry are the
obvious solutions to this limitation, although the prob-
lem with this is the varied criteria for selection for
retransplantation among different cardiac transplant
centers.
In conclusion, this study shows that cardiac retrans-
plantation appears to be a viable option in view of the
encouraging long-term survival achieved, except in
cases of acute graft failure and resistant acute rejection.
However, it seems that with larger numbers of patients
undergoing retransplantation, one would be able to
identify additional subgroups of patients in whom the
outcome is so poor as to make retransplantation unjus-
tifiable. The satisfactory long-term outcome in patients
with cardiac allograft failure caused by transplant-
related coronary disease, especially after a longer
retransplant interval, warrants retransplantation. This
approach appears valid so long as limited alternate
therapy for the treatment of end-stage heart disease
exists. Studies investigating mechanisms as well as
possible therapeutic solutions for transplant-related
coronary artery disease and rejection must continue to
make early and premature cardiac allograft failure a
preventable entity.
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Discussion
Dr William A. Baumgartner (Baltimore, Md). I congratu-
late Dr John and his colleagues on their retrospective analy-
sis of the results with cardiac retransplantation. Over a
21-year period, 43 patients or 4.5% of their total series under-
went cardiac retransplantation for cardiac failure resulting
from transplant-related coronary artery disease, rejection, and
early graft failure. They have demonstrated the futility of
retransplantation less than 6 months after the primary trans-
plantation, in particular in patients with rejection and early
graft failure. Actuarial survival in patients undergoing
retransplantation greater than 6 months after primary trans-
plantation compares favorably with their overall patient sur-
vival statistics. Multivariate analysis demonstrated that only
the interval between transplantation and an initial diagnosis
of ischemic cardiomyopathy were significant risk factors for
poor outcome. 
The issue of cardiac retransplantation is controversial with-
in the transplant community. It was a subject of debate at one
of the recent meetings of the ISHLT. In addition, the registry
supported by this society identified retransplantation as the
single most important risk factor for both 1- and 5-year mor-
tality after adult heart transplantation. At the most recent
ISHLT meetings, the registry report included a further analy-
sis of retransplantation. 
According to the registry, which comprises thousands of
patients, the 1-year retransplantation survival increases as the
time from the primary transplantation increases. The 1-year
transplant survival approaches 80%, similar to that of primary
transplantation. 
With the scarcity of donor organs, retransplantation often
poses a treatment dilemma. This dilemma of which patient
should receive the donor organ is reenacted in all of our indi-
vidual programs. Our policy of retransplantation is similar to
the authors’ current one. We have performed 16 retransplants
or 6% of the total number of our transplant procedures. Our
5- and 10-year actuarial survivals are 94% and 73%, respec-
tively. Our only indication for retransplantation has been
accelerated coronary arteriosclerosis. These findings support
the authors’ conclusions. 
I have 4 questions. Limiting retransplantation to those
patients who have survived for more than 6 months after their
primary procedure still causes occasional disagreements. In
regard to criteria, we believe strongly that patients considered
for retransplantation should meet all the selection criteria
imposed on patients undergoing a primary transplant proce-
dure. Dr John, would you mind expanding on your criteria for
retransplantation? 
Can you provide information regarding the extent of coro-
nary artery disease in your entire patient population? What is
the freedom from development of coronary artery disease at
10 years? 
Similarly, how many of your patients have died of coronary
artery disease? In our own series, several of the patients are
not candidates for retransplantation by the time significant or
advanced coronary artery disease develops, with its associated
left ventricular dysfunction. 
Finally, you have shown a relationship of rejection with
development of transplant-related coronary artery disease.
We have shown a relationship between the extent of ischemic
injury seen on the first cardiac biopsy specimen and the sub-
sequent development of coronary artery disease. Have you
seen any similar correlation?
Dr John. Thank you, Dr Baumgartner, for your kind and
very relevant comments. 
The two main indications for cardiac retransplantation
(since our selection criteria were revised in 1993) are as fol-
lows: (1) the presence of diffuse accelerated graft atheroscle-
rosis with concomitant left ventricular dysfunction that is not
amenable to angioplasty or coronary artery bypass grafting
and (2) graft failure as a result of acute rejection occurring
more than 6 months after transplantation. The exclusion cri-
teria for cardiac retransplantation are similar to those for pri-
mary cardiac transplantation but, if anything, are more strin-
gent. These include, for example, an upper age limit of 55
years (as compared with 65 years for primary transplantation)
and the presence of severe pulmonary hypertension (cutoff
for retransplant candidates is 3 Wood units as compared with
6 Wood units for primary transplants). The other exclusion
criteria include those that we apply to primary transplant can-
didates, such as the presence of active infection, recent or
active malignancy, human immunodeficiency virus disease,
and other factors. 
Regarding the development of coronary artery disease, in
our experience the freedom from transplant-related coro-
nary artery disease at 10 years is approximately 30% to
40%.
I do not have a specific answer for your third question con-
cerning the number of deaths from transplant-related coro-
nary artery disease. Deaths related to transplant-related coro-
nary artery disease fall into 3 major groups. One includes
patients who die before obtaining their first annual coronary
angiogram, and the postmortem examination reveals trans-
plant-related coronary artery disease. The second group
includes patients who are listed for retransplantation because
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of transplant-related coronary artery disease and die while
awaiting a donor organ. The third group of deaths includes
patients with transplant-related coronary artery disease who
are ineligible for retransplantation on the basis of our exclu-
sion criteria.
Finally, as you mentioned, our most significant association
with transplant-related coronary artery disease are immuno-
logic factors such as an earlier onset of high-grade rejection
and an increased cumulative frequency of high-grade rejec-
tion. We have not observed any relationship between
ischemic injury and transplant-related coronary artery dis-
ease. However, in our experience, the incidence of ischemic
injury on the first cardiac biopsy is relatively uncommon, in
the range of 5% of first cardiac biopsies.
Dr Robert W. Emery (Minneapolis, Minn). I am curious
about the fact that you found ischemic cardiomyopathy to be
a risk factor for retransplantation because you removed the
end-organ. This would imply an ongoing, underlying, un-
treated disease process. Do you think that the new heart will
be subject to this ongoing process? Do we need to look fur-
ther into why patients with ischemic cardiomyopathy have
retransplantation, or are there other comorbid risk factors that
would contribute to problems with retransplantation?
Dr John. Thank you, Dr Emery. The concern regarding
heart transplantation for ischemic cardiomyopathy is that
even though the end-organ is replaced, the basic risk factors
for the primary pathogenesis of the disease, namely, athero-
sclerosis, persists. It is important to be aggressive with mod-
ification of risk factors for atherosclerosis after heart trans-
plantation, such as the avoidance of cigarette smoking,
control of hypertension, and the use of lipid-lowering agents.
Otherwise, progressive atherosclerosis, both in the retrans-
planted heart and in other organs such as the kidney, will con-
tribute to a relatively poorer survival. 
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Notice of correction
In the October 1998 issue of the Journal, in the article by Alvarez and associates titled
“Rhabdomyolysis After Coronary Artery Bypass Grafting in a Patient Receiving Simvastatin”
(1998;116:654-5) the name of the second author was misspelled. The correct spelling of the name is
T. J. Rawdanowicz, MBBS.
